

Kelly E Dooley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1922989/publications.pdf>

Version: 2024-02-01

120
papers

5,373
citations

117571

34
h-index

95218

68
g-index

124
all docs

124
docs citations

124
times ranked

5730
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. <i>Clinical Infectious Diseases</i> , 2022, 74, 1604-1613.	2.9	15
2	Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps. <i>Lancet HIV</i> , 2022, 9, e130-e138.	2.1	7
3	A treatment recommender clinical decision support system for personalized medicine: method development and proof-of-concept for drug resistant tuberculosis. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 56.	1.5	7
4	Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1720-1724.	1.3	11
5	Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0239821.	1.4	15
6	Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1228-1235.	2.5	17
7	Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 1594-1601.	2.9	12
8	Tuberculous Meningitis in Children: Reducing the Burden of Death and Disability. <i>Pathogens</i> , 2022, 11, 38.	1.2	19
9	Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 215, 114774.	1.4	2
10	Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	5
11	Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 873-881.	2.3	10
12	Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1177-1185.	1.6	7
13	Resistance-Confering Mycobacterial Mutations and Quantification of Early Bactericidal Activity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 635-637.	2.5	4
14	Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	17
15	Optimising pyrazinamide for the treatment of tuberculosis. <i>European Respiratory Journal</i> , 2021, 58, 2002013.	3.1	15
16	A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 195, 113885.	1.4	4
17	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. <i>Clinical Pharmacokinetics</i> , 2021, 60, 685-710.	1.6	39
18	Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, India. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab097.	0.4	22

#	ARTICLE	IF	CITATIONS
19	Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. <i>New England Journal of Medicine</i> , 2021, 384, 1705-1718.	13.9	259
20	The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 637618.	1.6	4
21	QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 975-983.	4.6	60
22	Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab319.	0.4	2
23	A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1057-1065.	2.3	5
24	A leap forward in assessing host-directed therapies for tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 809-810.	5.2	1
25	A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1327-1335.	2.5	18
26	<i>In Vitro</i> Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessus. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0154521.	1.4	4
27	Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis. <i>Journal of Infectious Diseases</i> , 2021, 223, 1855-1864.	1.9	15
28	Pharmacological Considerations for Clinical Trials of Host-Directed Therapies for Tuberculosis. , 2021, , 311-332.		0
29	Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	2
30	Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 549-556.	2.9	50
31	Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes. <i>Clinical Infectious Diseases</i> , 2020, 70, 1463-1470.	2.9	21
32	Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model. <i>Clinical Infectious Diseases</i> , 2020, 70, 917-924.	2.9	14
33	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1774-1780.	2.9	59
34	Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort. <i>Clinical Infectious Diseases</i> , 2020, 71, 1419-1426.	2.9	19
35	Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. <i>Clinical Infectious Diseases</i> , 2020, 71, 517-524.	2.9	6
36	Drug resistant TB spine in a two year old child: A case report. <i>Indian Journal of Tuberculosis</i> , 2020, 67, 374-377.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	17
38	Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3433-3457.	1.3	23
39	Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 866-877.	2.5	22
40	Tenofovir alafenamide use in pregnant and lactating women living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 333-342.	1.5	28
41	Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1579-1580.	2.5	0
42	Mullen Scales of Early Learning Adaptation for Assessment of Indian Children and Application to Tuberculous Meningitis. <i>Journal of Tropical Pediatrics</i> , 2020, 67, .	0.7	1
43	Pharmacokinetics, SAfety/tolerability, and EFFicacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). <i>Trials</i> , 2020, 21, 181.	0.7	14
44	High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. <i>Contemporary Clinical Trials</i> , 2020, 90, 105938.	0.8	36
45	Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1416-1424.	2.5	42
46	Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	20
47	Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. <i>Lancet HIV,the</i> , 2020, 7, e401-e409.	2.1	41
48	Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa. <i>American Journal of Audiology</i> , 2020, 29, 199-205.	0.5	5
49	Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	37
50	Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 636-645.	2.7	18
51	Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 615-618.	1.5	6
52	Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology. <i>PLoS Medicine</i> , 2019, 16, e1002842.	3.9	30
53	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine,the</i> , 2019, 7, 820-826.	5.2	92
54	Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. <i>Lancet HIV,the</i> , 2019, 6, e201-e204.	2.1	24

#	ARTICLE	IF	CITATIONS
55	Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment. <i>Archives of Toxicology</i> , 2019, 93, 1385-1399.	1.9	16
56	Pharmacologic Research in Pregnant Women – Time to Get It Right. <i>New England Journal of Medicine</i> , 2019, 380, 1293-1295.	13.9	34
57	New Drugs for the Treatment of Tuberculosis. <i>Clinics in Chest Medicine</i> , 2019, 40, 811-827.	0.8	33
58	Intensified antibiotic treatment of tuberculosis meningitis. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 267-288.	1.3	34
59	The Global Landscape of Tuberculosis Therapeutics. <i>Annual Review of Medicine</i> , 2019, 70, 105-120.	5.0	24
60	Co-treatment of Tuberculosis and HIV: Pharmacologic Considerations. , 2019, , 239-267.		0
61	Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 921-929.	2.9	36
62	Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	40
63	Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Infected Children in India: Recommendations for Dose Modifications. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 733-741.	2.3	27
64	A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400mg in Pregnant Women. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1421-1433.	1.6	6
65	Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	37
66	The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. <i>Tuberculosis</i> , 2018, 108, 77-82.	0.8	14
67	Challenges of TB and HIV co-treatment. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 486-491.	1.5	31
68	The Global Neurological Burden of Tuberculosis. <i>Seminars in Neurology</i> , 2018, 38, 226-237.	0.5	37
69	Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 833-834.	0.6	0
70	High-Dose Rifampin: Shall We Be Bolder?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 558-560.	2.5	7
71	State-of-the-Art Review of HIV-TB Coinfection in Special Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1098-1109.	2.3	14
72	Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	31

#	ARTICLE	IF	CITATIONS
73	Tuberculosis Associated with HIV Infection. <i>Microbiology Spectrum</i> , 2017, 5, .	1.2	51
74	In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2320-2325.	1.3	30
75	Management of Tuberculosis in Special Populations. , 2017, , 141-190.		1
76	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> ,the, 2017, 5, 291-360.	5.2	459
77	The time has come: sparing injectables in paediatric MDR-TB. <i>Lancet Respiratory Medicine</i> ,the, 2017, 5, 245-246.	5.2	2
78	Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	29
79	Tuberculous meningitis. <i>Nature Reviews Neurology</i> , 2017, 13, 581-598.	4.9	337
80	Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1027-1036.	1.3	38
81	Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2028-2034.	1.3	9
82	Tuberculosis Associated with HIV Infection. , 2017, , 577-594.		1
83	Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis. <i>PLoS ONE</i> , 2017, 12, e0189101.	1.1	8
84	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. <i>PLoS Medicine</i> , 2017, 14, e1002202.	3.9	20
85	A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). <i>BMC Medicine</i> , 2016, 14, 51.	2.3	25
86	Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1234-1241.	1.4	32
87	Pharmacokinetic Interactions for Drugs with a Long Half-Life“Evidence for the Need of Model-Based Analysis. <i>AAPS Journal</i> , 2016, 18, 171-179.	2.2	23
88	Challenges in the clinical assessment of novel tuberculosis drugs. <i>Advanced Drug Delivery Reviews</i> , 2016, 102, 116-122.	6.6	25
89	Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. <i>Clinical Infectious Diseases</i> , 2016, 62, 761-769.	2.9	43
90	A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0154778.	1.1	26

#	ARTICLE	IF	CITATIONS
91	Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1106-1114.	1.3	98
92	Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 333-343.	2.5	102
93	Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3399-3405.	1.4	11
94	Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection. <i>Journal of Infectious Diseases</i> , 2015, 211, 197-205.	1.9	69
95	Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6073-6079.	1.4	17
96	Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment. <i>Future Microbiology</i> , 2015, 10, 1257-1260.	1.0	15
97	Determination of [¹¹ C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5768-5774.	1.4	47
98	Treatment Default amongst Patients with Tuberculosis in Urban Morocco: Predicting and Explaining Default and Post-Default Sputum Smear and Drug Susceptibility Results. <i>PLoS ONE</i> , 2014, 9, e93574.	1.1	38
99	Population Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Healthy Volunteers: Nonlinearities in Clearance and Bioavailability. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3035-3042.	1.4	28
100	Quantification of Rifapentine, a Potent Antituberculosis Drug, from Dried Blood Spot Samples Using Liquid Chromatographic-Tandem Mass Spectrometric Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6747-6757.	1.4	17
101	Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6406-6412.	1.4	57
102	Designing Drug Trials: Considerations for Pregnant Women. <i>Clinical Infectious Diseases</i> , 2014, 59, S437-S444.	2.9	82
103	Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5245-5252.	1.4	42
104	Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6366-6369.	1.4	112
105	World Health Organization Group 5 Drugs for the Treatment of Drug-Resistant Tuberculosis: Unclear Efficacy or Untapped Potential?. <i>Journal of Infectious Diseases</i> , 2013, 207, 1352-1358.	1.9	90
106	Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2780-2787.	1.4	85
107	Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 21-27.	0.9	161
108	TB and HIV Therapeutics: Pharmacology Research Priorities. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-9.	0.3	19

#	ARTICLE	IF	CITATIONS
109	Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 455-462.	0.9	71
110	Old Drugs, New Purpose: Retooling Existing Drugs for Optimized Treatment of Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2012, 55, 572-581.	2.9	57
111	Chapter 3: The Rifamycins: Renewed Interest in an Old Drug Class. <i>Progress in Respiratory Research</i> , 2011, , 18-24.	0.1	6
112	Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. <i>BMC Public Health</i> , 2011, 11, 140.	1.2	107
113	TMC207: the first compound of a new class of potent anti-tuberculosis drugs. <i>Future Microbiology</i> , 2010, 5, 849-858.	1.0	158
114	Tuberculosis and diabetes mellitus: convergence of two epidemics. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 737-746.	4.6	715
115	Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009, 80, 634-9.	0.6	105
116	Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4037-4042.	1.4	54
117	Drug Interactions Involving Combination Antiretroviral Therapy and Other Anti-Infective Agents: Repercussions for Resource-Limited Countries. <i>Journal of Infectious Diseases</i> , 2008, 198, 948-961.	1.9	78
118	Empiric Treatment of Community-Acquired Pneumonia with Fluoroquinolones, and Delays in the Treatment of Tuberculosis. <i>Clinical Infectious Diseases</i> , 2002, 34, 1607-1612.	2.9	115
119	A 39-Year-Old Man With Hip Pain and Respiratory Failure. <i>Chest</i> , 2002, 121, 1345-1349.	0.4	6
120	Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	1.3	3